Name | Number of supported studies | Average coverage | |
---|---|---|---|
oligodendrocyte | 17 studies | 46% ± 19% | |
epithelial cell | 3 studies | 24% ± 10% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 5 studies | 30% ± 14% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 96% | 6312.00 | 236 / 245 | 100% | 382.87 | 501 / 502 |
brain | 95% | 1496.84 | 2509 / 2642 | 68% | 8.04 | 480 / 705 |
liver | 96% | 661.40 | 216 / 226 | 63% | 5.54 | 254 / 406 |
kidney | 91% | 391.76 | 81 / 89 | 60% | 12.31 | 543 / 901 |
lung | 66% | 136.03 | 381 / 578 | 34% | 3.32 | 393 / 1155 |
breast | 58% | 195.42 | 266 / 459 | 32% | 2.76 | 363 / 1118 |
spleen | 90% | 231.49 | 217 / 241 | 0% | 0 | 0 / 0 |
skin | 33% | 56.40 | 605 / 1809 | 27% | 4.01 | 127 / 472 |
esophagus | 31% | 51.35 | 444 / 1445 | 27% | 2.65 | 50 / 183 |
ovary | 21% | 34.68 | 38 / 180 | 33% | 2.26 | 140 / 430 |
thymus | 24% | 32.59 | 156 / 653 | 25% | 1.33 | 149 / 605 |
bladder | 29% | 71.57 | 6 / 21 | 11% | 0.97 | 54 / 504 |
adrenal gland | 2% | 2.44 | 5 / 258 | 37% | 5.54 | 84 / 230 |
intestine | 27% | 80.37 | 260 / 966 | 8% | 0.71 | 42 / 527 |
uterus | 13% | 21.41 | 22 / 170 | 22% | 1.70 | 99 / 459 |
adipose | 29% | 56.38 | 355 / 1204 | 0% | 0 | 0 / 0 |
stomach | 9% | 12.65 | 32 / 359 | 10% | 0.90 | 30 / 286 |
pancreas | 0% | 0 | 0 / 328 | 19% | 3.31 | 33 / 178 |
tonsil | 0% | 0 | 0 / 0 | 18% | 1.22 | 8 / 45 |
blood vessel | 10% | 25.23 | 137 / 1335 | 0% | 0 | 0 / 0 |
heart | 7% | 11.47 | 62 / 861 | 0% | 0 | 0 / 0 |
muscle | 0% | 0.16 | 1 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0.13 | 1 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0035609 | Biological process | C-terminal protein deglutamylation |
GO_0006760 | Biological process | folic acid-containing compound metabolic process |
GO_0006508 | Biological process | proteolysis |
GO_0009986 | Cellular component | cell surface |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005886 | Cellular component | plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_0005737 | Cellular component | cytoplasm |
GO_0008233 | Molecular function | peptidase activity |
GO_1904492 | Molecular function | Ac-Asp-Glu binding |
GO_0004180 | Molecular function | carboxypeptidase activity |
GO_0016805 | Molecular function | dipeptidase activity |
GO_1904493 | Molecular function | tetrahydrofolyl-poly(glutamate) polymer binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0004181 | Molecular function | metallocarboxypeptidase activity |
Gene name | FOLH1 |
Protein name | Glutamate carboxypeptidase 2 (EC 3.4.17.21) (Cell growth-inhibiting gene 27 protein) (Folate hydrolase 1) (Folylpoly-gamma-glutamate carboxypeptidase) (FGCP) (Glutamate carboxypeptidase II) (GCPII) (Membrane glutamate carboxypeptidase) (mGCP) (N-acetylated-alpha-linked acidic dipeptidase I) (NAALADase I) (Prostate-specific membrane antigen) (PSM) (PSMA) (Pteroylpoly-gamma-glutamate carboxypeptidase) Folate hydrolase 1 FOLH1 protein |
Synonyms | FOLH PSMA PSM NAALAD1 GIG27 |
Description | FUNCTION: Has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity. Has a preference for tri-alpha-glutamate peptides. In the intestine, required for the uptake of folate. In the brain, modulates excitatory neurotransmission through the hydrolysis of the neuropeptide, N-aceylaspartylglutamate (NAAG), thereby releasing glutamate. Involved in prostate tumor progression.; FUNCTION: Also exhibits a dipeptidyl-peptidase IV type activity. In vitro, cleaves Gly-Pro-AMC. |
Accessions | ENST00000340334.11 [Q04609-7] E9PI29 E9PLV0 Q04609 ENST00000256999.7 [Q04609-1] ENST00000529648.1 ENST00000533034.1 [Q04609-9] ENST00000529117.1 Q2VPJ0 E9PKM3 E9PMK6 ENST00000525826.5 ENST00000533510.5 ENST00000356696.7 [Q04609-8] |